Following positive first-in-human Phase 1 single ascending dose and preliminary food-effect data with ART26.12, Artelo ...
Palatin Technologies, Inc. beats earnings expectations. Reported EPS is $-0.37, expectations were $-1.24333. Operator: Hello, ...
Lead Radio-DARPin MP0712 progressing in Phase 1/2a trial with multiple clinical sites opening and initial clinical data expected in 2026New data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results